The Effects of Bariatric Surgeries on Glucose Metabolism

Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-65
SponsorThe University of Texas Health Science Center at San Antonio

About this trial

The purpose of this study is learn the effect of gastric bypass surgery and sleeve gastrectomy on glucose metabolism mediated by neural and hormonal factors initiated after eating.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Hypoglycemic RYGB patients with documented blood glucose level <50 mg/dl

Asymptomatic individuals with bariatric surgery

Healthy non-surgical patients with no personal history of diabetes

Subjects must physically be able to come to our clinical research center Cedars-Sinai Medical Center

Disqualifiers

Active heart, lung, liver, gastrointestinal or kidney disease; unable to give informed consent; pregnancy; uncontrolled high blood pressure or high cholesterol; significant anemia (hemoglobin <11g/dL); prisoners or institutionalized individuals; type 2 diabetes mellitis; development of any serious medical or psychiatric illness during recruitment or studies;

RYGB patients will be disqualified if they have gastric outlet obstruction or severe diarrhea.

Healthy non-surgical patients with personal history of diabetes

History of glaucoma

Trial design

Design model

Crossover

Treatments tested in this trial

  • Exendin-(9-39)

    Drug

    A physiological study to evaluate the role of GLP-1 on glucose metabolism and insulin secretin after glucose and protein ingestion.

  • Atropine

    Drug

    A physiological study to evaluate the effect of neural activation on insulin secretion and glucose metabolism.

Treatment groups

200 Participants
are divided into 2 treatment groups
Group A: Exendin-(9-39)Experimental treatment 1 intervention
Group B: AtropineExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Insulin levels measured after nutrient ingestion

Time frame
Each study in the protocol is conducted up to seven hours with data collected at intervals specific to the individual study procedure.

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

The University of Texas Health Science Center at San Antonio

Lead sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborator